Amit Oza

28PUBLICATIONS
213CO-AUTHORS
ChemotherapyPredictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Cancer cell biology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (28)

|May 13, 2026
Maveropepimut-S, pembrolizumab and low dose cyclophosphamide in metastatic ovarian cancer: phase 1/2 PESCO trial.

|Mar 26, 2026
Preclinical Combination Targeting VEGF and PI3K in a Rare, Aggressive Mixed Endometrial Carcinoma: An Applied Case Report.

Nikolina Radulovich, Pamela Soberanis Pina, Molly L Udaskin

|Oct 30, 2025
Biomarkers in High-Grade Serous Ovarian Cancer: Context Is Everything.

Laura Venegas, Anjelica Hodgson, Amit M Oza

|Apr 22, 2025
ADAGIO: A Phase IIb, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine Serous Carcinoma.

Joyce F Liu, Nicoletta Colombo, Amit M Oza

|Mar 21, 2025
Precision Endocrine Therapy in Endometrial Cancer: Has Its Time Finally Come?

Vikas Garg, Amit M Oza

|Jan 21, 2025
Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial).

Husam A Alqaisi, David E Cohn, Jing-Yi Chern

Pageof 5

Frequent Collaborators

6 joint publications

Stephanie Lheureux

6 joint publications

Ainhoa Madariaga

4 joint publications

Ana Oaknin

4 joint publications

Eduardo Gonzalez-Ochoa